ArticleCancer cell2018
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Abstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 389 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
389citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
389 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Fear of Cancer Recurrence and Associated Factors Among Women with Female Cancer: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Immune-associated alternative splicing signatures define molecular subtypes in breast cancer.iScience · 2026Article
- A benchmark study of vision and pathology foundation models for computational pathology.Nature communications · 2026Article
- Targeting ZNF570 activates ferroptosis to reverse tamoxifen resistance in ER + breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.NPJ precision oncology · 2026Article
- Multiomic network analysis reveals conserved and subtype-specific cooperative microRNA regulators in breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Leveraging Dog Models to Uncover Human Cancer Insights.Research square · 2026Article
- Oncogenic receptor tyrosine kinase signaling is driven by the Golgi protein GOLPH3 and its interaction with MYO18A.Science signaling · 2026Article
- Pleiotrophin in Mammary Gland Development and Breast Cancer: A Comprehensive Review of the Evidence.Cells · 2026Review
- Deep interpretable radiogenomic workflow deciphers tumor microenvironment from breast MRI and identifies clinician-interpretable biomarkers.NPJ precision oncology · 2026Article
- The histone methyltransferase NSD3 oncogene triggers ribosomal DNA transcription, interfering with FOSL2 in cancer.Cell death & disease · 2026Article
- Characteristics of chromosomal instability‑related lncRNAs associated with progression and prognosis in breast cancer.Molecular medicine reports · 2026Article
- Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.NPJ precision oncology · 2026Article
- Alignment of spatial transcriptomics slices across diseases, platforms and conditions.Genome medicine · 2026Article
- The Model Related to Hypoxia and Endoplasmic Reticulum Stress Predicting Prognosis and Immunotherapy Response in Uterine Corpus Endometrial Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review.International journal of molecular sciences · 2026Review
- Regulators of homologous recombination deficiency identified by machine learning using somatic multi-omics data.Life science alliance · 2026Article
- Article
329 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Ashton C BergerThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Anil KorkutDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rupa S KanchiDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Apurva M HegdeDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Walter LenoirDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wenbin LiuDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yuexin LiuDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huihui FanCenter for Epigenetics, Van Andel Research Institute, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA.
Hui ShenCenter for Epigenetics, Van Andel Research Institute, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA.
Visweswaran RavikumarDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Arvind RaoDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Andre SchultzDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xubin LiDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pavel SumazinTexas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Cecilia WilliamsDepartment of Protein Sciences, CBH, KTH - Royal Institute of Technology, Science for Life Laboratory, Tomtebodavägen 23, 171 21 Solna, Sweden.
Pieter MestdaghDepartment of Pediatrics and Medical Genetics, Ghent University, Ghent, Belgium.
Preethi H GunaratneDepartment of Biology & Biochemistry, UH-Sequencing Core, University of Houston, Houston, TX 77204, USA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Christina YauBuck Institute of Research on Aging, Novato, CA 94945, USA; Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Reanne BowlbyBC Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada.
A Gordon RobertsonBC Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada.
Daniel G TiezziBreast Disease and Gynecologic Oncology Division - Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, 3900 Bandeirantes Avenue, Ribeirão Preto, SP 14048-900, Brazil.
Chen WangDepartment of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA; Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Andrew D CherniackThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Nicole M KudererAdvanced Cancer Research Group, Seattle, Washington, and Center for Cancer Innovation, Department of Medicine, University of Washington, WA 98195, USA.
Janet S RaderDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Rosemary E ZunaPathology Department, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alexander J LazarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Akinyemi I OjesinaDepartment of Epidemiology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Clement AdebamowoDepartment of Epidemiology and Public Health, Institute of Human Virology and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Institute of Human Virology, Abuja, Nigeria.
Sally N AdebamowoDepartment of Epidemiology and Public Health, Institute of Human Virology and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Keith A BaggerlyDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ting-Wen ChenTexas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Bioinformatics Center, Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan.
Hua-Sheng ChiuTexas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Steve LefeverDepartment of Pediatrics and Medical Genetics, Ghent University, Ghent, Belgium.
Liang LiuDepartment of Cancer Biology, Wake Forest Baptist Health Center, Winston Salem, NC 27157, USA.
Karen MacKenzieSchool of Women's and Children's Health, University of New South Wales, Sydney, Australia.
Sandra OrsulicWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jason RoszikDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carl Simon ShelleyLeukemia Therapeutics, LLC, Hull, MA 02045, USA.
Qianqian SongDepartment of Cancer Biology, Wake Forest Baptist Health Center, Winston Salem, NC 27157, USA.
Christopher P VellanoDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Cancer Genome Atlas Research Network
John N WeinsteinDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jweinste@mdanderson.org.
Gordon B MillsDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: gmills@mdanderson.org.
Douglas A LevineGynecologic Oncology, Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA. Electronic address: douglas.levine@nyumc.org.
Rehan AkbaniDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rakbani@mdanderson.org.
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MLarge Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7MThe Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BROADDUS, RUSSELL R · 2003 to 2020
$32.0MGene Expression Patterns in Human Tumors Identified Using Transcript SequencingU24CA143848 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2009 to 2016
$20.8MGenome Characterization Center (GCC)U24CA143867 · NCI · BROAD INSTITUTE, INC. · PI GABRIEL, STACEY, MEYERSON, MATTHEW L. · 2009 to 2016
$17.0MThe Cancer Genome Atlas Data Analysis CenterU24CA143845 · NCI · BROAD INSTITUTE, INC. · PI CHIN, LYNDA, GETZ, GAD A · 2009 to 2016
$16.0MHarvard Genome Characterization CenterU24CA144025 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUCHERLAPATI, RAJU S. · 2009 to 2016
$14.0MThe USC-JHU Cancer Epigenome Characterization CenterU24CA143882 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BAYLIN, STEPHEN B., WEISENBERGER, DANIEL JOSEPH · 2009 to 2016
$13.3MNCI NIH HHS P30 CA016087NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA163722NCI NIH HHS U01 CA168394NCI NIH HHS U01 CA217842NCI NIH HHS U24 CA143799NCI NIH HHS U24 CA143835NCI NIH HHS U24 CA143840NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA143845NCI NIH HHS U24 CA143848NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA143866NCI NIH HHS U24 CA143867NCI NIH HHS U24 CA143882NCI NIH HHS U24 CA143883NCI NIH HHS U24 CA144025NCI NIH HHS U24 CA199461NCI NIH HHS U24 CA210949NCI NIH HHS U24 CA210950NCI NIH HHS U24 CA210957NCI NIH HHS U24 CA210990NHGRI NIH HHS U54 HG003067NHGRI NIH HHS U54 HG003079NHGRI NIH HHS U54 HG003273
Abstract
We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of four gynecological types plus breast. Our aims were to identify shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets. We found 61 somatic copy-number alterations (SCNAs) and 46 significantly mutated genes (SMGs). Eleven SCNAs and 11 SMGs had not been identified in previous TCGA studies of the individual tumor types. We found functionally significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and gene/lncRNA interaction networks. Pathway analysis identified subtypes with high leukocyte infiltration, raising potential implications for immunotherapy. Using 16 key molecular features, we identified five prognostic subtypes and developed a decision tree that classified patients into the subtypes based on just six features that are assessable in clinical laboratories.
Indexed as
DNA Copy Number VariationsGene Regulatory NetworksMutationBreast NeoplasmsDatabases, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenital Neoplasms, FemaleHumansOrgan SpecificityPrognosisReceptors, EstrogenRNA, Long NoncodingReceptors, EstrogenRNA, Long Noncodingbreast cancercervical cancergynecologic canceromicsovarian cancerpan-gynecologicTCGAThe Cancer Genome Atlasuterine canceruterine carcinosarcoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.